|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:25–29. 2015. View Article : Google Scholar
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moore TH, King AJ, Evans M, Sharp D,
Persad R and Huntley AL: Supportive care for men with prostate
cancer: Why are the trials not working? A systematic review and
recommendations for future trials. Cancer Med. 4:1240–1251. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hudson SV, O'Malley DM and Miller SM:
Achieving optimal delivery of follow-up care for prostate cancer
survivors: Improving patient outcomes. Patient Relat Outcome Meas.
6:75–90. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miyamoto H, Messing EM and Chang C:
Androgen deprivation therapy for prostate cancer: Current status
and future prospects. Prostate. 61:332–353. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Helsen C, Van den Broeck T, Voet A,
Prekovic S, Van Poppel H, Joniau S and Claessens F: Androgen
receptor antagonists for prostate cancer therapy. Endocr Relat
Cancer. 21:T105–T118. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu B, Huang Y, Niu X, Tao T, Jiang L, Tong
N, Chen S, Liu N, Zhu W and Chen M: Hsa-miR-146a-5p modulates
androgen-independent prostate cancer cells apoptosis by targeting
ROCK1. Prostate. 75:1896–1903. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khanmi K, Ignacimuthu S and Paulraj MG:
MicroRNA in prostate cancer. Clin Chim Acta. 451:154–160. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fang YX and Gao WQ: Roles of microRNAs
during prostatic tumorigenesis and tumor progression. Oncogene.
33:135–147. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hassan O, Ahmad A, Sethi S and Sarkar FH:
Recent updates on the role of microRNAs in prostate cancer. J
Hematol Oncol. 5:92012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hsu TI, Hsu CH, Lee KH, Lin JT, Chen CS,
Chang KC, Su CY, Hsiao M and Lu PJ: MicroRNA-18a is elevated in
prostate cancer and promotes tumorigenesis through suppressing STK4
in vitro and in vivo. Oncogenesis. 3:e992014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu
M, Tepper CG, Evans CP, Kung HJ and deVere White RW: An
androgen-regulated miRNA suppresses Bak1 expression and induces
androgen-independent growth of prostate cancer cells. Proc Natl
Acad Sci USA. 104:19983–19988. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang L, Li B, Li L and Wang T:
MicroRNA-497 suppresses proliferation and induces apoptosis in
prostate cancer cells. Asian Pac J Cancer Prev. 14:3499–3502. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nazarov PV, Reinsbach SE, Muller A, Nicot
N, Philippidou D, Vallar L and Kreis S: Interplay of microRNAs,
transcription factors and target genes: Linking dynamic expression
changes to function. Nucleic Acids Res. 41:2817–2831. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cellini F, Morganti AG, Genovesi D,
Silvestris N and Valentini V: Role of microRNA in response to
ionizing radiations: Evidences and potential impact on clinical
practice for radiotherapy. Molecules. 19:5379–5401. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dias DC, Dolios G, Wang R and Pan ZQ:
CUL7: A DOC domain-containing cullin selectively binds Skp1. Fbx29
to form an SCF-like complex. Proc Natl Acad Sci USA.
99:16601–16606. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huber C, Dias-Santagata D, Glaser A,
O'Sullivan J, Brauner R, Wu K, Xu X, Pearce K, Wang R, Uzielli ML,
et al: Identification of mutations in CUL7 in 3-M syndrome. Nat
Genet. 37:1119–1124. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu X, Sarikas A, Dias-Santagata DC, Dolios
G, Lafontant PJ, Tsai SC, Zhu W, Nakajima H, Nakajima HO, Field LJ,
et al: The CUL7 E3 ubiquitin ligase targets insulin receptor
substrate 1 for ubiquitin-dependent degradation. Mol Cell.
30:403–414. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin P, Fu J, Zhao B, Lin F, Zou H, Liu L,
Zhu C, Wang H and Yu X: Fbxw8 is involved in the proliferation of
human choriocarcinoma JEG-3 cells. Mol Biol Rep. 38:1741–1747.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shi D, Tan Z, Lu R, Yang W and Zhang Y:
MicroRNA-218 inhibits the proliferation of human choriocarcinoma
JEG-3 cell line by targeting Fbxw8. Biochem Biophys Res Commun.
450:1241–1246. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ,
Lee KH, Yeh SD, Hong TM and Chen YL: MicroRNA-320 suppresses the
stem cell-like characteristics of prostate cancer cells by
downregulating the Wnt/beta-catenin signaling pathway.
Carcinogenesis. 34:530–538. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu C, Kelnar K, Vlassov AV, Brown D, Wang
J and Tang DG: Distinct microRNA expression profiles in prostate
cancer stem/progenitor cells and tumor-suppressive functions of
let-7. Cancer Res. 72:3393–3404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jin M, Zhang T, Liu C, Badeaux MA, Liu B,
Liu R, Jeter C, Chen X, Vlassov AV and Tang DG: miRNA-128
suppresses prostate cancer by inhibiting BMI-1 to inhibit
tumor-initiating cells. Cancer Res. 74:4183–4195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kurisetty VV, Lakshmanaswamy R and
Damodaran C: Pathogenic and therapeutic role of miRNAs in breast
cancer. Front Biosci (Landmark Ed). 19:1–11. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Okabe H, Lee SH, Phuchareon J, Albertson
DG, McCormick F and Tetsu O: A critical role for FBXW8 and MAPK in
cyclin D1 degradation and cancer cell proliferation. PLoS One.
1:e1282006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang H, Chen Y, Lin P, Li L, Zhou G, Liu
G, Logsdon C, Jin J, Abbruzzese JL, Tan TH and Wang H: The
CUL7/F-box and WD repeat domain containing 8 (CUL7/Fbxw8) ubiquitin
ligase promotes degradation of hematopoietic progenitor kinase 1. J
Biol Chem. 289:4009–4017. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tsunematsu R, Nishiyama M, Kotoshiba S,
Saiga T, Kamura T and Nakayama KI: Fbxw8 is essential for Cul1-Cul7
complex formation and for placental development. Mol Cell Biol.
26:6157–6169. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Molinari M: Cell cycle checkpoints and
their inactivation in human cancer. Cell Prolif. 33:261–274. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hartwell LH and Weinert TA: Checkpoints:
Controls that ensure the order of cell cycle events. Science.
246:629–634. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chiang NJ, Lin CI, Liou JP, Kuo CC, Chang
CY, Chen LT and Chang JY: A novel synthetic microtubule inhibitor,
MPT0B214 exhibits antitumor activity in human tumor cells through
mitochondria-dependent intrinsic pathway. PLoS One. 8:e589532013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
King KL and Cidlowski JA: Cell cycle and
apoptosis: Common pathways to life and death. J Cell Biochem.
58:175–180. 1995. View Article : Google Scholar : PubMed/NCBI
|
